Amgen Inc. (AMGN) Invests $650M to Expand Puerto Rico Biologics Facility, Adds 750 Jobs

In a recent analysis, we identified the 12 Most Undervalued Dow Stocks to Buy According to Analysts, and among them is Amgen Inc.

Amgen Inc. (NASDAQ:AMGN), a prominent player in the biotechnology field focusing on groundbreaking therapies for complex cancers and other serious health conditions, is set to bolster its U.S. manufacturing infrastructure. Recently, the company announced a significant investment of $650 million to expand its biologics facility located in Juncos, Puerto Rico. This expansion, expected to commence in September 2025, will leverage advanced technologies aimed at improving production efficiency as well as operational resilience. It’s projected that this initiative will create approximately 750 new job opportunities, encompassing both construction and skilled manufacturing positions. This strategy is particularly strategic in light of the recent 100% tariffs on imported pharmaceuticals imposed during the Trump administration, as Amgen’s domestic manufacturing efforts will provide a shield against these tariffs and enhance the security of its supply chain.

The Puerto Rico expansion follows Amgen’s earlier significant investments of $900 million in Ohio and $1 billion in North Carolina, underscoring the company’s commitment to scaling its production capabilities to accommodate a growing product pipeline. These strategic investments position Amgen to effectively meet increasing demand while maintaining flexibility in its operations across critical U.S. locations.

Financially, Amgen reported robust Q2 2025 performance, with revenues climbing 9% year-over-year to $9.2 billion and GAAP earnings per share skyrocketing by an impressive 92%. Although there has been a slight recent decline in stock price due to broader market fluctuations, analysts remain optimistic. Many consider Amgen Inc. (NASDAQ:AMGN) to be one of the most undervalued stocks within the biotech sector.

While we acknowledge AMGN’s potential as a viable investment, it is essential to highlight that certain AI stocks may present even greater upside opportunities and lower associated risks. For investors interested in an extremely undervalued AI stock poised to capitalize on the trends of Trump-era tariffs and the onshoring movement, we invite you to check our complimentary report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.